News
ATRC
23.45
+1.52%
0.35
Weekly Report: what happened at ATRC last week (0408-0412)?
Weekly Report · 3d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 4d ago
Press Release: AtriCure to Announce First Quarter 2024 Financial Results
AtriCure to announce first quarter 2024 financial results on Wednesday, May 1, 2024. Atricure is a leading innovator in surgical treatments and therapies for atrial fibrillation and post-operative pain management. The company will host an audio webcast at 4:30 p.m. Eastern Time.
Dow Jones · 04/10 12:03
Key Takeaways From AtriCure Analyst Ratings
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation and other conditions. The company has a 12-month price target of $48.0. Atricure has been downgraded by 4 analysts in the last three months. The firm has an average of $42.00 price targets for the next 12 months. It is a leading provider of ablation devices for cardiac surgery.
Benzinga · 04/10 12:01
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Sight Sciences (SGHT)
TipRanks · 04/10 09:40
Weekly Report: what happened at ATRC last week (0401-0405)?
Weekly Report · 04/08 11:37
Weekly Report: what happened at ATRC last week (0325-0329)?
Weekly Report · 04/01 11:33
Oppenheimer: S&P 500 top might not come until 2025; spotlights infrastructure stocks
Oppenheimer: S&P 500 top might not come until 2025; spotlights infrastructure stocks. Oppenheimer argued that the S&p 500 is poised for a move higher. The firm also pointed to the Global X U.S. Infrastructure Development ETF as a buying opportunity.
Seeking Alpha · 03/25 15:19
Weekly Report: what happened at ATRC last week (0318-0322)?
Weekly Report · 03/25 11:37
AtriCure on Pace for Longest Losing Streak Since September 2022 -- Data Talk
AtriCure, Inc. (ATRC) is currently at $28.40, down $1.33 or 4.47%. Down 12 of the past 13 days; currently down nine consecutive days. Down 67.41% from its all-time closing high of $87.14.
Dow Jones · 03/22 16:51
Weekly Report: what happened at ATRC last week (0311-0315)?
Weekly Report · 03/18 11:35
Weekly Report: what happened at ATRC last week (0304-0308)?
Weekly Report · 03/11 11:31
Weekly Report: what happened at ATRC last week (0226-0301)?
Weekly Report · 03/04 11:35
RiverPark/Next Century Growth Fund Q4 2023 Investor Letter
RiverPark/Next Century Growth Fund returned 4.75% in the fourth quarter of 2023 vs. The total return of the Russell 2000 Growth Index of 12.75%. The Fund is monitoring potential growth headwinds in this choppy macro environment. Investor sentiment continues to swing wildly. The Fund continues to invest in the fastest growing companies in America.
Seeking Alpha · 02/29 15:15
Weekly Report: what happened at ATRC last week (0219-0223)?
Weekly Report · 02/26 11:50
Sum Up The Parts: VBK Could Be Worth $274
NASDAQ · 02/22 15:04
Weekly Report: what happened at ATRC last week (0212-0216)?
Weekly Report · 02/19 11:52
AtriCure Price Target Raised to $58.00/Share From $57.00 by UBS
Dow Jones · 02/16 18:24
AtriCure Is Maintained at Buy by UBS
Dow Jones · 02/16 18:24
AtriCure Price Target Cut to $42.00/Share From $50.00 by Stifel
Dow Jones · 02/16 15:15
More
Webull provides a variety of real-time ATRC stock news. You can receive the latest news about Atricure through multiple platforms. This information may help you make smarter investment decisions.
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.